Lung Cancer
Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG�)Versus Alectinib (ALECENSA�) in Advanced Anaplastic Lymphoma Kinase-Positive Non�Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI�)
- Details
ClinicalTrials.gov ID:
NCT03596866
Diagnosis Type:
NA
USOR Number:
- Address
1441 N Beckley Ave, Suite 102
Dallas, TX 75203
P: (214) 943-9911